Jump to content

Help with results


Recommended Posts

Herpes simplex 1 igg 33.20 reference range <0.90 negative

herpes simple 2igg 0.09 reference range <0.90 negative 

Herpes simplex 1&2 igm 1.80 reference range <0.90 negative

equivocal range 0.90-1.09

Edited by Janedoe2325
Link to post
Share on other sites

Hey @Janedoe2325 we can help you here.

The results indicate you have HSV-1. This will almost undoubtedly be an oral infection from your youth.

You are very clearly negative for HSV-2 and thus do not carry this particular virus.

The IgM test is useless as can be triggered positive from time to time by your HSV-1 infection.

Does this help with your concerns?

Link to post
Share on other sites
1 hour ago, Janedoe2325 said:

@WilsoInAusomg are you sure ? When they called me for the results they told me i had genital herpes.

Yes very, very sure. The only way anyone can tell you that you have genital herpes is if they have taken a genital swab of lesions and tested it using PCA/culture. 

Some people do have genital HSV-1 usually from receiving oral sex and having an outbreak genitally.

Do you have any reason at all to suspect genital herpes? An outbreak or a partner tell you they had genital herpes?

Link to post
Share on other sites

@Janedoe2325 I’m really glad you did come across this site. I can’t believe you were told what you were told. There are however quite a few stories like yours that pop up from time to time on this website. There are some very uneducated doctors and others on this topic and the correct interpretation of tests. 
The only thing I can think of is that people get concerned when they see a non-zero number. However this is just the way ELISA based tests work, they are only zero if they fail. Otherwise if the person does not carry the virus being tested for, they are a number often between 0.05 and 0.35 say. Such a result like yours is a minimum value and indicates a complete absence of the relevant antibody being searched for.

Maybe they got confused with the IgM antibody test that in your case was testing for a non specific HSV related antibody. It therefore means that you have either type 1 OR 2 but the IgG clarifies truly which type(s) you have. In your case, type 1 only. This is something 70% of adults will have.

Link to post
Share on other sites

Hey @Janedoe2325 trust you are well today!

Your HSV-1 number is perfectly normal for a long term infection, neither high or low, but just perfect. No need to read more than that into an ELISA IgG test result!

You can absolutely resume your normal sex life, there is no need to do anything different.

  • Like 1
Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



  • Donate

    If Honeycomb has helped you, please help us by making a donation so we can provide you with even better features and services.

  • The Hive is Thriving!

    • Total Topics
      71,957
    • Total Posts
      486,520
  • 0_unsure-if-it-is-herpes.png

    Nervous about dating with herpes? Skip "the talk" and browse profiles here.

  • Posts

    • CHT
      so, you tested positive for GHSV1 via the swab test?  Not by an IgG antibody blood test? Are the OBs severe?  Are they coming often?    GHSV1 in its initial stages (early infection) can cause outbreaks.... the good news is that your odds of outbreaks is significantly lower than those with HSV2 and the number of outbreaks are also much less with GHSV1 than HSV2 especially as time goes on.... on average you may see only one outbreak per year versus 4 to 5 for those with HSV2.... the severity of the outbreaks from GHSV1 are also milder than HSV2 (you may not even notice them with time or go completely asymptomatic).  You may not even need antivirals as time goes on. 
    • Liv25
      The chapstick is called Docoshield and it is on Amazon. Just wanted to pass this along! I have been using this and it brings me a lot of comfort and it has excellent reviews. They also made this chapstick with lysine in it. Hope this helps anyone who needs it! 
    • BabyGirl
      I just stared dating someone who does not have HSV.How long after the sore is healed should I wait before having sex?  I’ve had HSV2 for over 10 years. I rarely have outbreaks going months even years until recently. When I do I get some tingles and one sore in the same spot. But recently, In the last 3 months it’s happened twice. 🤦🏼‍♀️
    • JDMT_176
      If you want to know whats going on when applying it, this was the only study I found describing it. Hard to read through as very technical, but am copy paste parts I found of use. Tables also useful to show which genes are expressed more.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416766/   "A petrolatum donut was applied with a cotton swab to form about a 1 cm diameter donut on skin on the inner aspect of the upper arm. Then a separate cotton swab was dipped in a 2% SADBE solution (w/v) in DMSO, and the swab was then used to apply about 10–20 mg of solution over about a 1 cm diameter circle within the petrolatum donut. Immediately after application, the application site was covered with TEGADERM. Subjects were advised to remove the TEGADERM and rinse and wipe the spot 3 h later.   "Thus in essentially every case, the SADBE treatment changed the group A subjects by day 57 to make them much more like the group B and C subjects who have better immune control of their HSV‐1 infection than the group A subjects were on day 1.   "Others have previously shown that CD8+ T cells are important in controlling herpes labialis outbreaks.23, 24, 25, 26, 27, 28, 29, 30, 31, 32 Our data are consistent with this. The helper/cytotoxic cell ratio (CD4+/CD8+ ratio) was 5.25 in group A versus 3.07 and 3.15, respectively in groups B and C (Table (Table3).3). The P‐value is less than 0.20 for comparisons of group A to both groups B and C, and if groups B and C are pooled and compared to group A the P‐value is 0.065, almost significant. This is consistent with prior evidence discussed below that CD8+ T cells are important and effective in controlling HSV recurrences.   "Consistent with our finding lower anti‐HSV‐1 IgG levels correlate with better control of HSV‐1 outbreaks, Spruance et al. also found lower serum anti‐HSV‐1 antibodies in HSV seropositive patients with a history of frequent herpes labialis than in seropositive persons with no history of herpes labialis.33   "Several prior reports also found IFN‐gamma to be important in controlling HSV infection and reducing HSV outbreaks. Dobbs et al28 showed that CD8+ T cells were able to clear an HSV‐2 infection in transgenic mice, but that efficacy was blocked in vivo by anti‐IFNG IgG. Liu et al31 showed that CD8+ T‐cells could prevent HSV‐1 reactivation from latency in excised trigeminal ganglia (TG), and that IFN‐gamma protein was produced by the CD8+ T cells, and that neutralization of IFN‐γ significantly enhanced the rate of HSV‐1 reactivation from latency in TG cultures. Spruance et al33 found that IFN‐gamma protein levels in PBMC supernatants stimulated with HSV‐1‐infected cell extracts were lower in frequent herpes labialis sufferers than HSV‐1 seropositive controls, consistent with the present result for IFNG gene expression in PBMC stimulated with heat‐killed HSV‐1. McKenna et al7 assayed IFN‐gamma in medium of PBMCs cultured in vitro and stimulated with inactivated HSV‐1 and found IFN‐gamma was at higher concentrations in medium of PBMCs from infrequent herpes labialis sufferers than frequent sufferers, also consistent with our findings. Cunningham et al34 showed higher interferon levels (including alpha, gamma, and lambda) in supernatants of PBMCs stimulated with heat‐killed HSV‐1 virus correlated with longer time to next herpes labialis recurrence. Carr et al35 showed that transgenic expression of IFNG could prevent HSV‐1 reactivation in a mouse model.
    • JDMT_176
      Hi Kurdt- I was thinking back in 2018-2019 there was several threads from viral frog that he was applying a 2% solution very frequently. Like several times a week. From what I gather- it didnt work for him at the time. I think too much applied caused immune chaos or something.  The most recent Square X trial was terminated but this was the dosing frequency that was used in the trial below: I was planning on using Group C protocol. Group A is most frequent. Something to think about.  https://clinicaltrials.gov/ct2/show/results/NCT03521479?term=squarex&draw=1&rank=4   Protocol:  Arm/Group Title Group A Group B Group C Group D  Arm/Group Description Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).   Adverse Reaction Table: Arm/Group Title Group A Group B Group C Group D  Arm/Group Description: Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6. Squaric Acid Dibutyl Ester: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Overall Number of Participants Analyzed 10 10 10 10 Measure Type: Number Unit of Measure: events         Localized reaction (rash, erythema, itching/pruritus, warmth/burning) at application site 24 14 17 6 Generalized adverse events (related, possible or greater) 2 3 1 0 Generalized adverse event (unrelated) 4 7 6 4  
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.